The House bill differs from a similar Senate bill in that it does not provide a path for FDA approval of follow-on biologics.
但是在参议院的另一个类似法案中，FDA并没有得到审批“后继生物药”的权限。
The House bill differs from a similar Senate bill in that it does not provide a path for FDA approval of follow-on biologics.
但是在参议院的另一个类似法案中，FDA并没有得到审批“后继生物药”的权限。
应用推荐